Erectile dysfunction in diabetes mellitus: A review

The International Diabetes Federation estimates that globally there are 425 million people with diabetes. Estimates of the prevalence of erectile dysfunction (ED) in men with diabetes range from 20% to 85% in different studies. Among men with ED, those with diabetes are likely to experience the prob...

Full description

Bibliographic Details
Main Authors: Deepak K Jumani, Omkar Patil
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Diabetology
Subjects:
Online Access:http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=1;spage=1;epage=7;aulast=Jumani
id doaj-bd534a239b624b46841e6e29f93aee87
record_format Article
spelling doaj-bd534a239b624b46841e6e29f93aee872020-11-25T02:53:17ZengWolters Kluwer Medknow PublicationsJournal of Diabetology2078-76852020-01-011111710.4103/jod.jod_42_18Erectile dysfunction in diabetes mellitus: A reviewDeepak K JumaniOmkar PatilThe International Diabetes Federation estimates that globally there are 425 million people with diabetes. Estimates of the prevalence of erectile dysfunction (ED) in men with diabetes range from 20% to 85% in different studies. Among men with ED, those with diabetes are likely to experience the problem 10–15 years earlier than men without diabetes. This review aims to provide an update of the epidemiology, pathophysiology and management of ED in diabetes patients in India. The proposed mechanisms of ED in diabetic patients include elevated advanced glycation end-products and increased levels of oxygen-free radicals, impaired nitric oxide (NO) synthesis, increased endothelin B receptor binding sites and ultrastructural changes, upregulated RhoA/Rho-kinase pathway, NO-dependent selective nitrergic nerve degeneration and impaired cyclic guanosine monophosphate-dependent kinase-1. Modifiable risk factors for ED include smoking, lack of physical activity, wrong diets, overweight or obesity, metabolic syndrome and excessive alcohol consumption. Therefore, the promotion of healthful lifestyles would yield great benefits in reducing the burden of ED. The treatment of diabetic ED is multimodal. The treatment of the underlying hyperglycaemia and comorbidities is of utmost importance to prevent the progression of the disease. The peripherally acting oral phosphodiesterase type 5 inhibitors are the mainstay of oral medical treatment of ED in diabetics. Vacuum erection devices are an additional a non-invasive treatment option. The local administration of vasoactive medication through urethral suppository or intracorporal injection can be effective with minimal side-effects.http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=1;spage=1;epage=7;aulast=Jumanidiabetes mellituserectile dysfunctionphosphodiesterase type 5 inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Deepak K Jumani
Omkar Patil
spellingShingle Deepak K Jumani
Omkar Patil
Erectile dysfunction in diabetes mellitus: A review
Journal of Diabetology
diabetes mellitus
erectile dysfunction
phosphodiesterase type 5 inhibitors
author_facet Deepak K Jumani
Omkar Patil
author_sort Deepak K Jumani
title Erectile dysfunction in diabetes mellitus: A review
title_short Erectile dysfunction in diabetes mellitus: A review
title_full Erectile dysfunction in diabetes mellitus: A review
title_fullStr Erectile dysfunction in diabetes mellitus: A review
title_full_unstemmed Erectile dysfunction in diabetes mellitus: A review
title_sort erectile dysfunction in diabetes mellitus: a review
publisher Wolters Kluwer Medknow Publications
series Journal of Diabetology
issn 2078-7685
publishDate 2020-01-01
description The International Diabetes Federation estimates that globally there are 425 million people with diabetes. Estimates of the prevalence of erectile dysfunction (ED) in men with diabetes range from 20% to 85% in different studies. Among men with ED, those with diabetes are likely to experience the problem 10–15 years earlier than men without diabetes. This review aims to provide an update of the epidemiology, pathophysiology and management of ED in diabetes patients in India. The proposed mechanisms of ED in diabetic patients include elevated advanced glycation end-products and increased levels of oxygen-free radicals, impaired nitric oxide (NO) synthesis, increased endothelin B receptor binding sites and ultrastructural changes, upregulated RhoA/Rho-kinase pathway, NO-dependent selective nitrergic nerve degeneration and impaired cyclic guanosine monophosphate-dependent kinase-1. Modifiable risk factors for ED include smoking, lack of physical activity, wrong diets, overweight or obesity, metabolic syndrome and excessive alcohol consumption. Therefore, the promotion of healthful lifestyles would yield great benefits in reducing the burden of ED. The treatment of diabetic ED is multimodal. The treatment of the underlying hyperglycaemia and comorbidities is of utmost importance to prevent the progression of the disease. The peripherally acting oral phosphodiesterase type 5 inhibitors are the mainstay of oral medical treatment of ED in diabetics. Vacuum erection devices are an additional a non-invasive treatment option. The local administration of vasoactive medication through urethral suppository or intracorporal injection can be effective with minimal side-effects.
topic diabetes mellitus
erectile dysfunction
phosphodiesterase type 5 inhibitors
url http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=1;spage=1;epage=7;aulast=Jumani
work_keys_str_mv AT deepakkjumani erectiledysfunctionindiabetesmellitusareview
AT omkarpatil erectiledysfunctionindiabetesmellitusareview
_version_ 1724725516579110912